CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
Ciltacabtagene autoleucel 治疗多发性骨髓瘤
英文原题：Ciltacabtagene autoleucel for the treatment of multiple myeloma.
查看英文原题
Ciltacabtagene autoleucel for the treatment of multiple myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
多发性骨髓瘤（MM）的治疗选择不断增加，但患者通常仍需接受多线治疗，且后续每线治疗的疗效往往逐渐下降。靶向B细胞成熟抗原（BCMA）的CAR-T 细胞疗法的发展打破了这一规律。在促使美国食品药品监督管理局（FDA）批准BCMA CAR-T 疗法ciltacabtagene autoleucel（cilta-cel）的临床试验中，既往接受过多线治疗的患者获得了深度且持久的应答。本综述总结cilta-cel现有临床试验数据，包括值得关注的不良事件，并讨论可能推动MM治疗模式改变的正在开展的研究。此外，本文还探讨cilta-cel在真实世界应用中目前面临的问题。
展开英文摘要原文
While treatment options for multiple myeloma (MM) are continuing to expand, this disease remains one characterized by requiring multiple lines of therapy, with generally decreasing effectiveness of each subsequent line. The development of B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has proven an exception to this rule.
In the trial that led to approval of the BCMA CAR T-cell therapy ciltacabtagene autoleucel (cilta-cel) by the U. S. Food and Drug Administration (FDA), deep and durable response rates were observed in heavily pretreated patients. In this review we summarize the available clinical trial data for cilta-cel, including discussion on notable adverse events, as well as discuss ongoing studies that are likely to lead to paradigm changes in the management of MM.
In addition, we discuss the issues that currently surround the real-world utilization of cilta-cel.
论文信息
- 作者
- Holstein SA
- 单位
- Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA. sarah.holstein@unmc.edu.United States
- 文献类型
- 综述
- 期刊
- Drugs of today (Barcelona, Spain : 1998)2023 Jan
- 原文标识
- PubMed 36811414 · DOI 10.1358/dot.2023.59.1.3509751